
Glucosylceramide synthase inhibitors - Pipeline Insight, 2025
Description
DelveInsight’s, “Glucosylceramide synthase inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Glucosylceramide synthase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Glucosylceramide synthase inhibitors: Overview
Glucosylceramide synthase (GCS) is a glucosyltranserase that processes the sphingolipid ceramide. The product, glucosylceramide, can be further elaborated with a variety of oligosaccharides to become glycosphingolipids called gangliosides (most notably GM1 and GM3). Excess glycosphingolipids have been correlated with a variety of human diseases. The pathologies associated with lysosomal storage disorders (Gaucher, Fabry, Tay-Sachs, and Sandhoff) stem from improper disposal of glucosylceramide and other glycosphingolipids. Gaucher disease (GD) is caused by a deficiency of glucocerebrosidase and the consequent lysosomal accumulation of unmetabolized glycolipid substrates. Substrate reduction therapy through inhibition of glucosylceramide synthase (GCS) has also been shown to effectively treat the visceral disease.
Report Highlights
This segment of the Glucosylceramide synthase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Glucosylceramide synthase inhibitors Emerging Drugs
Further product details are provided in the report……..
Glucosylceramide synthase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Glucosylceramide synthase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Glucosylceramide synthase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Glucosylceramide synthase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glucosylceramide synthase inhibitors drugs.
Glucosylceramide synthase inhibitors Report Insights
Current Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Glucosylceramide synthase inhibitors: Overview
Glucosylceramide synthase (GCS) is a glucosyltranserase that processes the sphingolipid ceramide. The product, glucosylceramide, can be further elaborated with a variety of oligosaccharides to become glycosphingolipids called gangliosides (most notably GM1 and GM3). Excess glycosphingolipids have been correlated with a variety of human diseases. The pathologies associated with lysosomal storage disorders (Gaucher, Fabry, Tay-Sachs, and Sandhoff) stem from improper disposal of glucosylceramide and other glycosphingolipids. Gaucher disease (GD) is caused by a deficiency of glucocerebrosidase and the consequent lysosomal accumulation of unmetabolized glycolipid substrates. Substrate reduction therapy through inhibition of glucosylceramide synthase (GCS) has also been shown to effectively treat the visceral disease.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Glucosylceramide synthase inhibitors R&D. The therapies under development are focused on novel approaches for Glucosylceramide synthase inhibitors.
This segment of the Glucosylceramide synthase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Glucosylceramide synthase inhibitors Emerging Drugs
- Lucerastat: Idorsia Pharmaceuticals
- Venglustat: Sanofi
Further product details are provided in the report……..
Glucosylceramide synthase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Glucosylceramide synthase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Glucosylceramide synthase inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Glucosylceramide synthase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Glucosylceramide synthase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glucosylceramide synthase inhibitors drugs.
Glucosylceramide synthase inhibitors Report Insights
- Glucosylceramide synthase inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Glucosylceramide synthase inhibitors drugs?
- How many Glucosylceramide synthase inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Glucosylceramide synthase inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glucosylceramide synthase inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Glucosylceramide synthase inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Idorsia Pharmaceuticals
- Sanofi
- Lucerastat
- Venglustat
- Sinbaglustat
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Glucosylceramide synthase inhibitors: Overview
- Structure
- Mechanism of Action
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Glucosylceramide synthase inhibitors– DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Glucosylceramide synthase inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Glucosylceramide synthase inhibitors Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- Lucerastat: Idorsia Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Sinbaglustat: Idorsia Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Glucosylceramide synthase inhibitors Key Companies
- Glucosylceramide synthase inhibitors Key Products
- Glucosylceramide synthase inhibitors- Unmet Needs
- Glucosylceramide synthase inhibitors- Market Drivers and Barriers
- Glucosylceramide synthase inhibitors- Future Perspectives and Conclusion
- Glucosylceramide synthase inhibitors Analyst Views
- Glucosylceramide synthase inhibitors Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.